Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1Breast 1

Conditions

Neoplasms 3Colorectal Neoplasms 2Carcinoma, Non-Small-Cell Lung 2Triple Negative Breast Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Solid Tumor Cancers 1Ovarian Neoplasms 1Neoplasm Metastasis 1Lethal Congenital Contracture Syndrome 2 1Head and Neck Neoplasms 1Fallopian Tube Neoplasms 1Endometrial Neoplasms 1Breast Neoplasms 1

Interventions

pembrolizumab 59Gemcitabine 37Biopsy 33Specimen Handling 32Paclitaxel 30Magnetic Resonance Spectroscopy 30Nivolumab 29Cisplatin 26Carboplatin 25Irinotecan 24Cyclophosphamide 23Fluorouracil 22Bevacizumab 22Docetaxel 21Oxaliplatin 19Leucovorin 18Ipilimumab 17Cetuximab 17Capecitabine 17130-nm albumin-bound paclitaxel 16Everolimus 15Albumin-Bound Paclitaxel 15Trastuzumab 13olaparib 12Pemetrexed 12Erlotinib Hydrochloride 12spartalizumab 11Sorafenib 11Radiosurgery 11trastuzumab deruxtecan 10

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Neoplasm Metastasis × seribantumab × Clear all
NCT01209195 2016-09-08

A Study of MM-121 in Combination With Paclitaxel in Patients With Advanced Gynecologic and Breast Cancers

Merrimack Pharmaceuticals

Phase 1 Completed
41 enrolled 14 charts
BreastGynecologic

Breast Neoplasms, Fallopian Tube Neoplasms, Neoplasm Metastasis, Ovarian Neoplasms, Endometrial Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡